ROLE OF SYSTEMATIC INFLAMMATION IN THE DEVELOPMENT OF COMORBIDITY IN CASE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
https://doi.org/10.21292/2075-1230-2017-95-6-61-66
Abstract
Often local inflammation develops into systemic one with total inflammatory response of endotheliocytes, plasma and cellular blood factors, connective tissue, and at the final stages it is manifested through microcirculatory disorders in vital organs and tissues. At present two aspects are being investigated related to systemic inflammation in chronic obstructive pulmonary disease (COPD). Firstly, it is the evaluation of inflammatory load through testing the level of inflammation markers in blood. Secondly, now it is generally recognized that a number of typical extrapulmonary disorders and concurrent diseases develops in COPD patients. Regardless of these general pathogenic mechanisms, the one thing is clear: cardiovascular diseases, body weight loss, osteoporosis and a number of other extrapulmonary manifestations of COPD are related to systematic inflammatory response.
About the Authors
V. A. Nikitin
Voronezh State Medical academy named After N. N. Burdenko
Russian Federation
Russian Federation
Vladimir A. Nikitin - Candidate of Medical Sciences, Assistant of Therapy Department.
10, Studencheskaya St., Voronezh, 394036, Phone: +7 (473) 236-68-31
L. V. Vаsilievа
Voronezh State Medical academy named After N. N. Burdenko
Russian Federation
Russian Federation
Liudmila V. Vasilieva - Doctor of Medical Sciences, Professor, Head of Therapy Department.
10, Studencheskaya St., Voronezh, 394036, Phone: +7 (473) 236-68-31
E. M. Tolstykh
Voronezh State Medical academy named After N. N. Burdenko
Russian Federation
Russian Federation
Elena M. Tolstykh - Candidate of Medical Sciences, Assistant of Department for Propedeutics of Internal Diseases.
10, Studencheskaya St., Voronezh, 394036, Phone: +7 (473) 236-68-31
A. S. Nogovitsynа
lipetsk Municipal Polyclinic no. 7
Russian Federation
Russian Federation
Anna S. Nogovitsyna - Deputy Head Doctor for Medical Issues.
34, Merkulova St., Lipetsk, 398046
References
1. Vertkin А.L. et al. Comorbidity in COPD: role of chronic systemic inflammation. Ross. Med. Journal, 2014, no. 11, pp. 811. (In Russ.)
2. Voronkova O.O. Sostoyanie sistemy provospalitelnykh tsitokinov i nespetsificheskikh markerov vospaleniya u bolnykh KHOBL i dinamika ikh na fone lecheniya bronkholiticheskimi sredstvami. Diss. kand. med. nauk. [State of anti-inflammatory cytokine system and non-specific inflammation markers in COPD patients and its changes when treated by bronchodilators. Cand. Diss.]. Moscow, 2006, 112 p.
3. Globalnaya strategiya diagnostiki, lecheniya i profilaktiki khronicheskoy obstruktivnoy bolezni legkikh (peresmotr 2007). (Russ. Ed.: Global Strategy for Diagnosis, Management, and Prevention of COPD (revision as of 2011)). Edited by A.G. Chuchalin, Moscow, Atmoshera Publ., 2008, 100 p.
4. Gusev E.Yu. et al. Chronic systemic inflammation as a typical disorder. Tsitokiny i Vospaleniye, 2008, vol. 7, no. 4, pp. 3-10. (In Russ.)
5. Dvoretskiy L.I. Anemia in those suffering from chronic obstructive pulmonary disease: comorbidity or systemic manifestation? Pulmonoloiya, 2012, no. 6, pp. 5-11. (In Russ.)
6. Zhdanov V.F. Kliniko-statisticheskaya kharakteristika bolnykh nespetsificheskimi zabolevaniyami legkikh s sistemnoy arterialnoy gipertenziey. Аktualnye problemy pulmonologii: cb. nauch. tr. [Clinical and statistic characteristics of those suffering from non-specific pulmonary diseases and systemic arterial hypertension. Actual issues of pulmonology. Coll. of articles]. Moscow, Leningrad, 1991, pp. 89-93.
7. Zadionchenko V.S. et al. Endothelium dysfunction and apoptosis process in those with chronic cor pulmonale. Ross. Kardiologichesky Journal, 2007, vol. 63, no. 1, pp. 84-87. (In Russ.)
8. Zadionchenko V.S. et al. Clinical and functional specific features of arterial hypertension in COPD patients. Ross. Med. Journal, 2003, vol. 9, pp. 535-539. (In Russ.)
9. Zarubina E.G., Karpechkina Yu.L., Prokhorenko I.O. Impact of metabolic syndrome on the rate of development of ischemic heart disease in chronic obstructive pulmonary disease patients. Vestnik Meditsinskogo Instituta «REАVIZ»: Reabilitatsiya, Vrach i Zdorovye, 2011, no. 1, pp. 27-33. (In Russ.)
10. Klinicheskie rekomendatsii: khronicheskaya obstruktivnaya bolezn legkikh. [Clinical recommendations: chronic obstructive pulmonary disease]. Edited by A.G. Chuchalin, Moscow, Atmoshera Publ., 2003, pp. 168.
11. Kuzubova N.А. et al. Role of systemic inflammation and endothelium dysfunction in the development of left ventricular failure in chronic obstructive pulmonary disease patients. Pulmonoloiya, 2013, no. 4, pp. 41-45. (In Russ.)
12. Leschenko I.V., Baranova I.I. Inflammation biomarkers in chronic obstructive pulmonary disease. Pulmonoloiya, 2012, no. 2, pp. 108-117. (In Russ.)
13. Ryazanov А.S., Kireev S.А., Eremenko N.N. Specific clinical course of COPD in metabolic syndrome: role of systemic inflammation. Ozhirenie i Metabolizm, 2010, no. 2, pp. 49-51. (In Russ.)
14. Serebryakova V.I. Kliniko-patologicheskie osobennosti neyroehndokrinnoy regulyatsii pri sochetanii arterialnoy gipertenzii s labilnoy i stabilnoy obstruktsii bronkhov v vozrastnom i polovom aspekte, korrektsiya vyyavlennykh narusheniy. Diss. dokt. med. nauk. [Clinical and pathologic specific features of neuroendocrinal regulation with concurrent arterial hypertension with instable and stable bronchial obstruction in the age and gender aspect, management of detected disorders. Doct. Diss.]. St. Petersburg, 1998, 55 p. Tuberculosis and Lung Diseases, Vol. 95, No. 6, 2017
15. Chereshnev V.А., Gusev E.Yu., Yurchenko T.N. System inflammation – myth or reality? Vestnik Rossiiskoy Akademii Nauk, 2004, vol. 74, no. 3, pp. 219-227. (In Russ.)
16. Chicherina E.N., Shipitsina V.V., Malykh S.V. Comparative characteristics of clinical and functional disorders of the cardiovascular system in those suffering from chronic obstructive bronchitis. Pulmonoloiya,2003, no. 6, pp. 97-102. (In Russ.)
17. Shmelev E.I. Khronicheskaya obstruktivnaya bolezn legkikh. [Chronic Obstructive Lung Disease]. Moscow, 2003,
18. Brajer B. et al. Concentration of matrix metalloproteinase-9 in serum of patients with chronic obstructive pulmonary disease and a degree of airway obstruction and disease progression. J. Physiol. Pharmacol., 2008, vol. 59, suppl. 6, pp. 145-152.
19. Brekke P.H. et al. Troponin-T elevation and long-term mortality after chronic obstructive pulmonary disease exacerbation. Eur. Respir. J., 2008, vol. 31, pp. 563-570.
20. Cazzola M. et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J., 2008, vol. 31, pp. 416-469.
21. Francios L.G. et al. Markers of disease severity in chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther., 2006, vol. 19, pp. 189-199.
22. Friedman G.D., Klatsky A.L., Siegelaub A.B. Lung function and risk of myocardial nfarction and sudden cardiac death. N. Engl. J. Med., 1976, vol. 294, pp. 1071-1075.
23. Groenewegen K.H. et al. COSMIC Study Group. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest, 2008, vol. 133, pp. 350-357.
24. He J.Q. et al. Associations of IL-6 polymorphisms with lung function decline and COPD. Thorax, 2009, vol. 64, pp. 698-704.
25. Jenkins A.B., Markovic T.P. Carbohydrate intake and short-term regulation of leptin in humans. Diabetologia, 1997, vol. 40, pp. 348-351.
26. Kaptoge S. et al. Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet, 2010, vol. 375, pp. 132-140.
27. Kataoka H. et al. The role of nitric oxide and the renin-angiotensin system in salt-restricted Dahl rats. Am. J. Hypertens., 2001, vol. 14, no. 3, pp. 276-285.
28. Lind L. Circulating markers of inflammation and atherosclerosis. L. Lind. Atherosclerosis, 2003, vol. 169, pp. 203-214.
29. Majo J. et al. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur. Respir. J., 2001, vol. 17, pp. 946-953.
30. Manisto J., Haahtela T. Leukotreiene receptor blockers and leukotriene synthesis inhibitors. Nord. Med., 1997, vol. 112, no. 4, pp. 122-125.
31. Mantzoroz C.S. The role of leptin in human obesity and disease: a review of current evidence. Ann. Intern. Med., 1999, vol. 130, pp. 671-680.
32. Pinto-Plata V.M. et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax, 2006, vol. 61, pp. 23-28.
33. Raisz L.G. Physiology and pathophysiology of bone remodeling. Clin. Chem., 1999, vol. 45, pp. 1353-1358.
34. Ridker P.M., Rifai N., Rose L. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med., 2002, vol. 347, pp. 1557-1565.
35. Sabit. R. et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2007, vol. 175, pp. 1259-1265.
36. Sauerwein H.P., Schols A.M. Glucose metabolism in chronic lung disease. Clin. Nutr., 2002, vol. 21, pp. 367-371.
37. Schols A.M. Pulmonary cachexia. Int. J. Cardiol., 2002, vol. 85, pp. 101-110.
38. Schunemann H.J. et al. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the. Buffalo Health Study. Chest, 2000, vol. 118, pp. 656-664.
39. Sin D.D. et al. Surfactant protein D: a lung specific biomarker in COPD?. Ther. Adv. Respir. Dis., 2008, no. 2, pp. 65-74.
40. Zacho J. et al. Genetically elevated C-reactive protein and ischemic vascular disease. N. Engl. J. Med., 2008, vol. 359, pp. 1897-1908.
Review
For citations:
Nikitin V.A., Vаsilievа L.V., Tolstykh E.M., Nogovitsynа A.S. ROLE OF SYSTEMATIC INFLAMMATION IN THE DEVELOPMENT OF COMORBIDITY IN CASE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Tuberculosis and Lung Diseases. 2017;95(6):61-66. (In Russ.) https://doi.org/10.21292/2075-1230-2017-95-6-61-66
Views:
1616
Email this article 